Timothy William Jones

Timothy William Jones

Auto-generated profile, based on publicly available information

Timothy William Jones

Department of Endocrinology and Diabetes, Perth Children’s Hospital, Nedlands, Australia

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2013 in JAMA
Verified
Journal Article
Closed access
PDF file
TLTrang T. Ly
Trang T. Ly
JNJennifer A. Nicholas
Jennifer A. Nicholas
ARAdam Retterath
Adam Retterath
ELEe Mun Lim
Ee Mun Lim
EDElizabeth A. Davis
Elizabeth A. Davis
TJTimothy W. Jones
Timothy W. Jones
Research from JAMA — Effect of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension vs Standard Insulin Pump Therapy on Hypoglycemia in Patients With Type 1 Diabetes — A Randomized Clinical Trial

5 June 2018 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
MAMary B. Abraham
Mary B. Abraham
TJTimothy W. Jones
Timothy W. Jones
DNDiana Naranjo
Diana Naranjo
BKBeate Karges
Beate Karges
AOAbiola Oduwole
Abiola Oduwole
DMDavid M. Maahs
David M. Maahs

11 October 2021 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
MAMary B. Abraham
Mary B. Abraham
MBMartin de Bock
Martin de Bock
GSGrant J. Smith
Grant J. Smith
JDJulie Dart
Julie Dart
JFJanice M. Fairchild
Janice M. Fairchild
SVSara Vogrin
Sara Vogrin
Over the past 2 decades, there have been significant innovations in the management of type 1 diabetes (T1D). Automation in closed-loop systems offers the potential to reduce diabetes burden and improve glucose profile.1 There are several automated insulin delivery platforms using various combinations of insulin pumps, continuous glucose monitor (CGM) systems, and algorithms. The MiniMed 670G (Medtronic) insulin pump was the first commercial system to be available after regulatory approval, based on findings from a 3-month single-arm observational study.2 The study also reported improved glycemic control, with increased time in range (TIR) and reductions in hemoglobin A1c (HbA1c), compared with baseline.3 The hybrid closed-loop (HCL) system uses a control algorithm that delivers insulin based on CGM glucose measures. However, meals must still be announced and an insulin bolus delivered according to meal carbohydrate content.

12 June 2013 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
SJS. R. Johnson
S. R. Johnson
MCM. N. Cooper
M. N. Cooper
EDE. A. Davis
E. A. Davis
TJT. W. Jones
T. W. Jones

30 November 2017 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
MAMary B. Abraham
Mary B. Abraham
JNJennifer A. Nicholas
Jennifer A. Nicholas
GSGrant J. Smith
Grant J. Smith
JFJanice M. Fairchild
Janice M. Fairchild
BKBruce R. King
Bruce R. King
OGon behalf of the PLGM Study Group
on behalf of the PLGM Study Group
OBJECTIVE Short-term studies with automated systems that suspend basal insulin when hypoglycemia is predicted have shown a reduction in hypoglycemia; however, efficacy and safety have not been established in long-term trials. RESEARCH DESIGN AND METHODS We conducted a 6-month, multicenter, randomized controlled trial in children and adolescents with type 1 diabetes using the Medtronic MiniMed 640G pump with Suspend before low (predictive low-glucose management [PLGM]) compared with sensor-augmented pump therapy (SAPT) alone. The primary outcome was percentage time in hypoglycemia with sensor glucose (SG) <3.5 mmol/L (63 mg/dL). RESULTS In an intent-to-treat analysis of 154 subjects, 74 subjects were randomized to SAPT and 80 subjects to PLGM. At baseline, the time with SG <3.5 mmol/L was 3.0% and 2.8% in the SAPT and PLGM groups, respectively. During the study, PLGM was associated with a reduction in hypoglycemia compared with SAPT (% time SG <3.5 mmol/L: SAPT vs. PLGM, 2.6 vs. 1.5, P < 0.0001). A similar effect was also noted in time with SG <3 mmol/L (P < 0.0001). This reduction was seen both during day and night (P < 0.0001). Hypoglycemic events (SG 20 min) also declined with PLGM (SAPT vs. PLGM: events/patient-years 227 vs. 139, P < 0.001). There was no difference in glycated hemoglobin (HbA1c) at 6 months (SAPT 7.6 ± 1.0% vs. PLGM 7.8 ± 0.8%, P = 0.35). No change in quality of life measures was reported by participants/parents in either group. There were no PLGM-related serious adverse events. CONCLUSIONS In children and adolescents with type 1 diabetes, PLGM reduced hypoglycemia without deterioration in glycemic control.

26 October 2018 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
MBMarie-Anne Burckhardt
Marie-Anne Burckhardt
ARAlison Roberts
Alison Roberts
GSGrant J. Smith
Grant J. Smith
MAMary B. Abraham
Mary B. Abraham
EDElizabeth A. Davis
Elizabeth A. Davis
TJTimothy W. Jones
Timothy W. Jones
OBJECTIVE This study aimed to explore the effect of continuous glucose monitors with remote monitoring on psychosocial outcomes in parents of children with type 1 diabetes. RESEARCH DESIGN AND METHODS Children with type 1 diabetes, aged 2–12 years, along with their parents, were studied in a randomized crossover study. They participated in two 3-month periods using conventional blood glucose monitoring (control) or the Dexcom G5 Mobile continuous glucose monitoring (CGM) system with remote monitoring (intervention). The primary outcome was parental fear of hypoglycemia score assessed by the Hypoglycemia Fear Survey. RESULTS Parental Hypoglycemia Fear Survey scores were lower while the child was using CGM with remote monitoring (P < 0.001). Furthermore, parental health-related quality of life and family functioning, stress, anxiety, and sleep measures also improved significantly after intervention. CONCLUSIONS CGM with remote monitoring was found to improve multiple measures of quality of life, reduce family stress, and improve parental sleep.